Who owns ATHIRA PHARMA INC?
- Ticker: LONA
- CUSIP Number: 04746l203
Tip: Access positions for across all investors
Analyze quarterly positions in Athira Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Athira Pharma stock
Who bought or sold ATHIRA PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Perceptive Advisors | 1.9M | $19M | 0% | Mar 2026 |
|
| ADAR1 Capital Management | 728k | $7.5M | 85% | Mar 2026 |
|
| Acorn Capital Advisors | 502k | $3.8M | 100% | Dec 2025 |
|
| NEA Management Company | 464k | $4.8M | 0% | Mar 2026 |
|
| Commodore Capital | 464k | $4.8M | 0% | Mar 2026 |
|
| TCG Crossover Management | 464k | $4.7M | 0% | Mar 2026 |
|
| Kalehua Capital Management | 394k | $4.0M | 100% | Mar 2026 |
|
| Vanguard Capital Management | 195k | $2.0M | 100% | Mar 2026 |
|
| Seven Fleet Capital Management | 165k | $1.7M | 29% | Mar 2026 |
|
| Vanguard Group | 154k | $1.2M | 0% | Dec 2025 |
|
| Simplify Asset Management | 149k | $1.5M | 0% | Mar 2026 |
|
| Propel Bio Management | 149k | $1.5M | 0% | Mar 2026 |
|
| Geode Capital Management | 80k | $826k | 160% | Mar 2026 |
|
| Renaissance Technologies | 75k | $569k | 45% | Dec 2025 |
|
| BlackRock | 56k | $576k | 49% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 40k | $412k | 100% | Mar 2026 |
|
| Bank of America Corporation | 33k | $335k | 100% | Mar 2026 |
|
| Millennium Management | 32k | $326k | -90% | Mar 2026 |
|
| Laird Norton Tyee Trust | 22k | $165k | 116% | Dec 2025 |
|
| Susquehanna International | 21k | $159k | 0% | Dec 2025 |
|
| Two Sigma Investments | 13k | $137k | 24% | Mar 2026 |
|
| State Street Corporation | 11k | $81k | 0% | Dec 2025 |
|
| Northern Trust | 11k | $79k | 100% | Dec 2025 |
|
| Acadian Asset Management | 10k | $105k | -73% | Mar 2026 |
|
| Advisor Group Holdings | 9.2k | $70k | 31% | Dec 2025 |
|
| Royal Bank of Canada | 2.2k | $23k | 3221% | Mar 2026 |
|
| Vanguard Global Advisers | 1.3k | $14k | 100% | Mar 2026 |
|
| UBS Group | 1.3k | $13k | -62% | Mar 2026 |
|
| Annis Gardner Whiting Capital Advisors | 1.0k | $10k | 100% | Mar 2026 |
|
| Morgan Stanley | 471.00 | $4.7k | 0% | Mar 2026 |
|
| Goss Wealth Management | 410.00 | $4.2k | 720% | Mar 2026 |
|
| Tower Research Capital | 379.00 | $2.9k | -41% | Dec 2025 |
|
| American Capital Advisory | 200.00 | $2.1k | 0% | Mar 2026 |
|
| Rothschild Investment | 150.00 | $1.5k | 0% | Mar 2026 |
|
| McIlrath & Eck | 82.00 | $843.001000 | 0% | Mar 2026 |
|
| Us Bancorp | 81.00 | $612.999900 | 0% | Dec 2025 |
|
| Global Retirement Partners | 52.00 | $393.000400 | 0% | Dec 2025 |
|
| Jones Financial Companies, L.L | 33.00 | $250.001400 | 0% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 23.00 | $236.000700 | 0% | Mar 2026 |
|
| SBI Securities | 12.00 | $123.000000 | 0% | Mar 2026 |
|
| Caitong International Asset Management | 6.00 | $61.999800 | 100% | Mar 2026 |
|
| Citigroup | 1.00 | $10.000000 | 100% | Mar 2026 |
|
Who sold out of Athira Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Pathstone Holdings | Dec 2025 | 39k | $279k |
| Jane Street | Dec 2025 | 13k | $100k |
| Scientech Research | Dec 2025 | 10k | $77k |
| Colony | Sep 2025 | 8.4k | $558k |
| Group One Trading | Dec 2025 | 69.00 | $521.998800 |
| Jpmorgan Chase & Co | Sep 2025 | 12.00 | $50.000400 |
| Barclays | Sep 2025 | 7.00 | $29.000300 |